Testing effectiveness (Phase 2)Not Yet RecruitingNCT07662720
What this trial is testing
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Glycyx Therapeutics 18